Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Morphosys Ag ADR (NQ: MOR )

18.07 +0.03 (+0.17%)
Streaming Delayed Price Updated: 9:35 AM EDT, Apr 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Morphosys Ag ADR

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Incyte Should Consider Significant Stock Buyback And Prioritize R&D, Analyst Recommends
Incyte acquires Escient Pharmaceuticals for $750 million, bolstering its pipeline. Cantor Fitzgerald initiates coverage with a Neutral rating, citing undervaluation concerns despite strong cash flow. 
Via Benzinga
MorphoSys’ Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis
From MorphoSys AG
Via Business Wire
MorphoSys' Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis
Via ACCESSWIRE
MorphoSys Announces U.S. Antitrust Clearance of Proposed Acquisition by Novartis Under HSR Act
Via ACCESSWIRE
MorphoSys: Q4 Earnings Insights
Via Benzinga
Earnings Outlook For MorphoSys
Via Benzinga
Invitation to MorphoSys' Full Year Results 2023 Conference Call on March 14, 2024
Via ACCESSWIRE
Dow Plummets on Rising Bond Yields, MCD Earnings
Via Talk Markets
Topics Stocks
Exposures US Equities
MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
From MorphoSys AG
Via Business Wire
Earnings Scheduled For March 13, 2024
Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarterly loss at $0.26 per share on revenue of $8.10 million. 
Via Benzinga
MorphoSys AG (NASDAQ: MOR) Near the Top of Equities by Percentage Gain on 2/5
Via Investor Brand Network
5 Biotechnology Stocks To Buy For A Stable Portfolio In 2024
Things have been looking better for the biotech industry in 2024 after a decent performance in 2023. Here is a look at some biotech stocks that may provide stability to one's portfolio throughout the... 
Via Talk Markets
3 Cancer-Fighting Biotech Stocks Showing Clinical Trial Promise
Discover the pivotal roles of cancer-fighting biotech stocks that are advancing cancer research and subsequently, their financial growth. 
Via InvestorPlace
Exit Now! 3 Biotech Stocks to Sell in February 2024
These biotech stocks to sell represent incredibly risky bets, amidst the sector's volatility and looming economic unpredictability. 
Via InvestorPlace
Novartis Agrees To Acquire German Blood Cancer-Drug Developer MorphoSys For €2.7B
Novartis' €2.7 billion public takeover offer for MorphoSys, unlocking a promising oncology pipeline with pelabresib and tulmimetostat. 
Via Benzinga
Biotech Stock MorphoSys Catapults 56% As Novartis Agrees To Buy It For $2.9 Billion
Novartis will add to its cancer treatment pipeline with via the German biotech. 
Via Investor's Business Daily
Why Is MorphoSys (MOR) Stock Up 50% Today?
News of a potential takeout bid for any company usually leads to a big surge. That's what investors are seeing today with MOR stock. 
Via InvestorPlace
Why Air Products and Chemicals Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Air Products and Chemicals, Inc. (NYSE: APD) fell sharply during Monday’s session after the company reported worse-than-expected first-quarter financial results and lowered FY24 adjusted EPS... 
Via Benzinga
MorphoSys Stock Soars After Report Says Novartis To Acquire Cancer-Drug Developer
Novartis is in advanced talks to acquire MorphoSys and appears to be beating out Incyte Corporation which has also made an offer to acquire MorphoSys. MorphoSys produces a lymphoma drug, Monjuvi, sold... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
MorphoSys Enters into Business Combination Agreement to be Acquired by Novartis for € 2.7 Billion Equity Value
Via ACCESSWIRE
Estée Lauder Posts Upbeat Earnings, Joins ON Semiconductor, Tyson Foods And Other Big Stocks Moving Higher On Monday
U.S. stocks traded lower, with the Dow Jones falling over 300 points on Monday. 
Via Benzinga
Topics Stocks
Exposures US Equities
MorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces Financial Liability
Via ACCESSWIRE
Philips Reports Q4 Results, Joins Ryanair And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Dow futures falling around 50 points on Monday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Why TransCode Therapeutics Shares Are Trading Lower By Over 24%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of TransCode Therapeutics, Inc. (NASDAQ: RNAZ) fell sharply during Friday’s session. TransCode Therapeutics priced a 5,942,623 share common stock offering at $1.22 per share. TransCode... 
Via Benzinga
Why Super Micro Computer Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket
Shares of Super Micro Computer, Inc. (NASDAQ: SMCI) rose sharply in pre-market trading after the company announced updated financial guidance for the second-quarter, which surpassed its previou 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
We're starting the final day of trading this week with a look at the biggest pre-market stock movers for Friday morning! 
Via InvestorPlace
iRobot, AST SpaceMobile And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures were higher this morning, with the Nasdaq futures gaining over 100 points on Friday. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.